Charles B. O'Keeffe - 09 Dec 2024 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Director
Signature
/s/ Charles B. O'Keeffe
Issuer symbol
CPRX
Transactions as of
09 Dec 2024
Net transactions value
+$160,400
Form type
4
Filing time
11 Dec 2024, 17:00:19 UTC
Previous filing
25 Nov 2024
Next filing
31 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise +1,413 +0.21% 687,137 09 Dec 2024 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $160,400 +40,000 +5.8% $4.01 727,137 10 Dec 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Restricted Stock Units Options Exercise $0 -1,413 -0.55% $0.000000 253,607 09 Dec 2024 Common Stock 1,413 Direct F1, F2, F3
transaction CPRX Options to purchase common stock Options Exercise $0 -40,000 -16% $0.000000 213,607 10 Dec 2024 Common Stock 40,000 $4.01 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Derivative securities vest in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026.
F3 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 9, 2024.
F4 Options vested in three annual tranches beginning on January 2, 2019.